Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 225

1.

The G-quadruplex ligand, SYUIQ-FM05, targets proto-oncogene c-kit transcription and induces apoptosis in K562 cells.

Shen FH, Jin J, Li J, Wang Y, Zhu SH, Lu YJ, Ou TM, Huang ZS, Huang M, Huang ZY.

Pharm Biol. 2013 Apr;51(4):447-54. doi: 10.3109/13880209.2012.738424. Epub 2013 Jan 30.

PMID:
23363047
2.

[A G-quadruplex ligand SYUIQ-5 induces autophagy by inhibiting the Akt-FOXO3a pathway in nasopharyngeal cancer cells].

Zhou WJ, Deng R, Feng GK, Zhu XF.

Ai Zheng. 2009 Oct;28(10):1049-53. Chinese.

PMID:
19799812
3.

Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis.

González I, Andreu EJ, Panizo A, Inogés S, Fontalba A, Fernández-Luna JL, Gaboli M, Sierrasesúmaga L, Martín-Algarra S, Pardo J, Prósper F, de Alava E.

Clin Cancer Res. 2004 Jan 15;10(2):751-61.

4.

Inhibition of cell proliferation by quindoline derivative (SYUIQ-05) through its preferential interaction with c-myc promoter G-quadruplex.

Ou TM, Lin J, Lu YJ, Hou JQ, Tan JH, Chen SH, Li Z, Li YP, Li D, Gu LQ, Huang ZS.

J Med Chem. 2011 Aug 25;54(16):5671-9. doi: 10.1021/jm200062u. Epub 2011 Jul 29.

PMID:
21774525
5.

Paradoxical and contradictory effects of imatinib in two cell line models of hormone-refractory prostate cancer.

Cardoso HJ, Vaz CV, Correia S, Figueira MI, Marques R, Maia CJ, Socorro S.

Prostate. 2015 Jun 15;75(9):923-35. doi: 10.1002/pros.22976. Epub 2015 Mar 18.

PMID:
25786656
6.

Senescence and telomere shortening induced by novel potent G-quadruplex interactive agents, quindoline derivatives, in human cancer cell lines.

Zhou JM, Zhu XF, Lu YJ, Deng R, Huang ZS, Mei YP, Wang Y, Huang WL, Liu ZC, Gu LQ, Zeng YX.

Oncogene. 2006 Jan 26;25(4):503-11.

PMID:
16170347
7.

Novel indoloquinoline derivative, IQDMA, induces G(2)/M phase arrest and apoptosis in A549 cells through JNK/p38 MAPK signaling activation.

Su JC, Lin KL, Chien CM, Lu CM, Chen YL, Chang LS, Lin SR.

Life Sci. 2009 Sep 23;85(13-14):505-16. doi: 10.1016/j.lfs.2009.08.006. Epub 2009 Aug 21.

PMID:
19699753
9.

Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.

Beppu K, Jaboine J, Merchant MS, Mackall CL, Thiele CJ.

J Natl Cancer Inst. 2004 Jan 7;96(1):46-55.

PMID:
14709738
10.

A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors.

Mahadevan D, Cooke L, Riley C, Swart R, Simons B, Della Croce K, Wisner L, Iorio M, Shakalya K, Garewal H, Nagle R, Bearss D.

Oncogene. 2007 Jun 7;26(27):3909-19. Epub 2007 Feb 26.

PMID:
17325667
11.

Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells.

Sambol EB, Ambrosini G, Geha RC, Kennealey PT, Decarolis P, O'connor R, Wu YV, Motwani M, Chen JH, Schwartz GK, Singer S.

Cancer Res. 2006 Jun 1;66(11):5858-66.

12.

Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1.

Arunasree KM, Roy KR, Anilkumar K, Aparna A, Reddy GV, Reddanna P.

Leuk Res. 2008 Jun;32(6):855-64. Epub 2008 Feb 20.

PMID:
18083230
13.

Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.

Nguyen TK, Rahmani M, Gao N, Kramer L, Corbin AS, Druker BJ, Dent P, Grant S.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2239-47.

14.

Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.

Hamaï A, Richon C, Meslin F, Faure F, Kauffmann A, Lecluse Y, Jalil A, Larue L, Avril MF, Chouaib S, Mehrpour M.

Oncogene. 2006 Dec 7;25(58):7618-34. Epub 2006 Sep 18. Erratum in: Oncogene. 2007 Feb 22;26(8):1256.

PMID:
16983347
15.

Oxidized LDL induces apoptosis of human retinal pigment epithelium through activation of ERK-Bax/Bcl-2 signaling pathways.

Yating Q, Yuan Y, Wei Z, Qing G, Xingwei W, Qiu Q, Lili Y.

Curr Eye Res. 2015 Apr;40(4):415-22. doi: 10.3109/02713683.2014.927507. Epub 2014 Jun 23.

PMID:
24956392
16.

Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway.

Peng CL, Guo W, Ji T, Ren T, Yang Y, Li DS, Qu HY, Li X, Tang S, Yan TQ, Tang XD.

Cancer Biol Ther. 2009 Sep;8(18):1729-36. Epub 2009 Sep 6.

PMID:
19633425
17.

Imatinib mesylate (STI571; Glivec)--a new approach in the treatment of biliary tract cancer?

Wiedmann M, Kreth F, Feisthammel J, Deininger M, Mössner J, Caca K.

Anticancer Drugs. 2003 Oct;14(9):751-60.

PMID:
14551510
18.

G-quadruplex ligand SYUIQ-5 induces autophagy by telomere damage and TRF2 delocalization in cancer cells.

Zhou WJ, Deng R, Zhang XY, Feng GK, Gu LQ, Zhu XF.

Mol Cancer Ther. 2009 Dec;8(12):3203-13. doi: 10.1158/1535-7163.MCT-09-0244.

19.

Antitumor effects of Isatin on human neuroblastoma cell line (SH-SY5Y) and the related mechanism.

Hou L, Ju C, Zhang J, Song J, Ge Y, Yue W.

Eur J Pharmacol. 2008 Jul 28;589(1-3):27-31. doi: 10.1016/j.ejphar.2008.04.061. Epub 2008 May 7.

PMID:
18561913
20.

Novel indoloquinoline derivative, IQDMA, inhibits STAT5 signaling associated with apoptosis in K562 cells.

Yang SH, Chien CM, Su JC, Chen YL, Chang LS, Lin SR.

J Biochem Mol Toxicol. 2008 Nov-Dec;22(6):396-404. doi: 10.1002/jbt.20254.

PMID:
19111001

Supplemental Content

Support Center